Extrapulmonary Tuberculosis—An Update on the Diagnosis, Treatment and Drug Resistance
Journal of Respiration · 26.05.2021 · 1 (2) · 141-164
DOI: 10.3390/jor1020015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Respiration, online erschienen am 26.05.2021. Verfasst von Radha Gopalaswamy und 3 weiteren Autor:innen. Die Arbeit wurde bisher 110-mal zitiert (Crossref) und nennt 222 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pathogenic Mycobacterium tuberculosis complex organisms (MTBC) primarily cause pulmonary tuberculosis (PTB); however, MTBC are also capable of causing disease in extrapulmonary (EP) organs, which pose a significant threat to human health worldwide. Extrapulmonary tuberculosis (EPTB) accounts for about 20–30% of all active TB cases and affects mainly children and adults with compromised immune systems. EPTB can occur through hematogenous, lymphatic, or localized bacillary dissemination from a primary source, such as PTB, and affects the brain, eye, mouth, tongue, lymph nodes of neck, spine, bones, muscles, skin, pleura, pericardium, gastrointestinal, peritoneum, and the genitourinary system as primary and/or disseminated disease. EPTB diagnosis involves clinical, radiological, microbiological, histopathological, biochemical/immunological, and molecular methods. However, only culture and molecular techniques are considered confirmatory to differentiate MTBC from any non-tuberculous mycobacteria (NTM) species. While EPTB due to MTBC responds to first-line anti-TB drugs (ATD), drug susceptibility profiling is an essential criterion for addressing drug-resistant EPTB cases (DR-EPTB). Besides antibiotics, adjuvant therapy with corticosteroids has also been used to treat specific EPTB cases. Occasionally, surgical intervention is recommended, mainly when organ damage is debilitating to the patient. Recent epidemiological studies show a striking increase in DR-EPTB cases ranging from 10–15% across various reports. As a neglected disease, significant developments in rapid and accurate diagnosis and better therapeutic interventions are urgently needed to control the emerging EPTB situation globally. In this review, we discuss the recent advances in the clinical diagnosis, treatment, and drug resistance of EPTB.
Zitieren
APA
Gopalaswamy, R., Dusthackeer, V. N. A., Kannayan, S., & Subbian, S. (2021). Extrapulmonary Tuberculosis—An Update on the Diagnosis, Treatment and Drug Resistance. Journal of Respiration, 1(2), 141-164. https://doi.org/10.3390/jor1020015
Vancouver
Gopalaswamy R, Dusthackeer VNA, Kannayan S, Subbian S. Extrapulmonary Tuberculosis—An Update on the Diagnosis, Treatment and Drug Resistance. Journal of Respiration. 2021;1(2):141-164. doi:10.3390/jor1020015
BibTeX
@article{Gopalaswamy2021,
author = {Gopalaswamy, Radha and Dusthackeer, V. N. Azger and Kannayan, Silambuchelvi and Subbian, Selvakumar},
title = {Extrapulmonary Tuberculosis—An Update on the Diagnosis, Treatment and Drug Resistance},
journal = {Journal of Respiration},
year = {2021},
volume = {1},
number = {2},
pages = {141--164},
doi = {10.3390/jor1020015}
}
EUVIMED